Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Politics Of Mega-Mergers: Health Care Reform And U.S. Biopharma Realignment

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck/Schering, Pfizer/Wyeth underscore sense of long-term structural change in U.S. pharma market.

You may also be interested in...

FTC Chairman To Be Jon Leibowitz: Will Reverse Payments Get More Scrutiny?

Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission

Merck/Schering: The Next Wave Of Consolidation

$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.

Medicare Price Negotiation “Not A Priority” For House Dems

Medicaid rebate increase and follow-on biologics could take $70 billion from pharma over 10 years, key staffer says—but industry should be happy with that trade.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts